Description
Contrast agents and radiopharmaceuticals have revolutionized in vivo imaging. Technical developments in contrast media and imaging techniques is combining with the trends toward both the functional and molecular understanding of disease to create a rapidly growing marketplace in these agents.
The introduction and now brisk ongoing development of contrast media for traditional radiography, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, positron-emission tomography (PET), and single-photon emission computed tomography (SPECT), are now allowing for the expansion of diagnostic capabilities of these modalities. Dozens of agents are being developed with the hopes of opening up new applications for existing modalities. While some agents will compete with existing agents while others aim to break new ground and provide a diagnostic assessment that is not currently available today.
This comprehensive study of the world market for contrast agents builds on the previous modality-focused reports of Kalorama’s Medical Imaging Markets series and includes:
- World and regional revenue forecasts for contrast agents and radiopharmaceuticals by modality through 2010.
- Market share of the major contrast agent supplers
- Procedure volumes by modality and region
- Estimates of the portion of procedures in each modality using contrast enhancement
- Contrast-enhancement products in development
The report also discusses technical developments and emerging application trends such as therapeutic monitoring, whole body screening, and guided therapeutic interventions, and how contrast agents are helping to expand imaging’s role in basic research and drug discovery/development. Specific advances in contrast agent-enabled diagnostics for mammography, Alzheimer’s, and other indications are also reviewed.
The report concludes with profiles of top suppliers and developers including:
- Acusphere Inc.
- Advanced Magnetics Inc.
- ART Advanced Research Technologies Inc.
- Bristol-Myers Squibb
- Boston Life Sciences
- Bracco SpA
- Cell Point
- Cytogen Corp.
- Daiichi Pharmaceutical Co. Ltd.
- Dendritic NanoTechnologies Inc.
- Dowpharma
- Draximage
- Epix Pharmaceuticals Inc.
- E-Z-EM Inc.
- GE Healthcare
- Guerbet Group
- Hovione FarmaCiencia SA
- Imcor Pharmaceutical Co.
- Immunomedics Inc.
- King Pharmaceuticals Inc.
- Luna nanoWorks
- Macrocyclics
- Mallinckrodt
- Palatin Technologies Inc.
- Pharmacyclics
- Point Biomedical Corp.
- Schering AG
Table of Contents
Chapter One: Executive Summary
- 1.1 The Role of Contrast
- 1.2 Use by Modality
- 1.2.1 X-Ray and CT
- 1.2.2 Ultrasound
- 1.2.3 MRI
- 1.2.4 Radiopharmaceuticals
- 1.3 World Market Summary
- 1.3.1 Market Drivers
- 1.3.2 Market Challenges
- 1.3.3 World Market Growth Analysis
- 1.4 Methodology
Chapter Two: Introduction
- 2.1 Overview
- 2.2 Perspective
- 2.3 Key Markets for Contrast Agents
- 2.3.1 Radiography (X-Ray) and Computed Tomography (CT)
- 2.3.2 Ultrasound
- 2.3.3 Magnetic Resonance Imaging (MRI)
- 2.3.4 Nuclear Medicine
- 2.3.4.1 Positron Emission Tomography (PET)
- 2.3.4.2 Single Photon Emission Computed Tomography SPECT
- 2.3.4.3 Gamma Cameras
- 2.4 Ionic and Non-Ionic Contrast Agents
- 2.5 Issues and Challenges
- 2.5.1 Adverse Events
- 2.5.2 Therapeutic Monitoring
- 2.5.3 Drug Delivery and Image Guided Interventions
- 2.5.4 Whole Body Screening
- 2.5.5 Technology Development
- 2.5.6 Combination Technology
Chapter Three: Promising Developments
- 3.1 Nuclear Imaging for Appendicitis
- 3.2 PET for Alzheimer’s
- 3.3 Contrast-Enhanced MRI Mammogram
- 3.4 Combined Contrast Enhanced MRI
- 3.5 Contrast Angiography
- 3.6 Avoiding Multiple MRIs
- 3.7 Chemical Shift Imaging
- 3.8 Perfusion CT
- 3.9 Multimodal Contrast
Chapter Four: Markets
- 4.1 Market Drivers
- 4.1.1 Targeted Imaging
- 4.1.2 The Promise of Increased Diagnostic Efficacy
- 4.1.3 Older Population
- 4.1.4 System Upgrades
- 4.2 Procedures and Reimbursement
- 4.3 Market Size and Outlook for Contrast Media
- 4.3.1 Agents in Development
- 4.3.2 Total Market Size and Forecast
- 4.3.3 Segment Market Forecasts
- 4.3.3.1 Radiography (X-Ray)
- 4.3.3.2 Computed Tomography (CT)
- 4.3.3.3 Ultrasound
- 4.3.3.4 Magnetic Resonance Imaging (MRI)
- 4.4 Market Size and Outlook for Molecular Imaging Agents
- 4.4.1 Products and Development
- 4.4.2 Market Forecast
- 4.5 Competitive Positions
Chapter Five: Company Profiles
- Acusphere Inc.
- Advanced Magnetics Inc.
- ART Advanced Research Technologies Inc.
- Bristol-Myers Squibb
- Boston Life Sciences
- Bracco SpA
- Cell Point
- Cytogen Corp.
- Daiichi Pharmaceutical Co. Ltd.
- Dendritic NanoTechnologies Inc.
- Dowpharma
- Draximage
- Epix Pharmaceuticals Inc.
- E-Z-EM Inc.
- GE Healthcare
- Guerbet Group
- Hovione FarmaCiencia SA
- Imcor Pharmaceutical Co.
- Immunomedics Inc.
- King Pharmaceuticals Inc.
- Luna nanoWorks
- Macrocyclics
- Mallinckrodt
- Palatin Technologies Inc.
- Pharmacyclics
- Point Biomedical Corp.
- Schering AG
List of Exhibits
Chapter One: Executive Summary
- Exhibit 1: Market Summary: World Market for Medical Contrast Media 2006-2010
Chapter Two: Introduction
- Exhibit 2: Key Medical Contrast Agents by Type
- Exhibit 3: Advantages of Non-Ionic Contrast Media
Chapter Four: Markets
- Exhibit 4: Estimated Worldwide Medical X-Ray Procedure Volume by Region (U.S., E.U., ROW) 2005
- Exhibit 5: Estimated Worldwide Medical MRI Procedure Volume by Region (U.S., E.U., ROW) 2005
- Exhibit 6: Estimated Worldwide Medical CT Procedure Volume by Region (U.S., E.U., ROW) 2005
- Exhibit 7: Estimated Worldwide Medical PET Procedure Volume by Region (U.S., E.U., ROW) 2005
- Exhibit 8: Estimated Percentage of Imaging Procedures Employing Contrast Agents by Modality (X-Ray, CT, MRI, Ultrasound, PET, SPECT)
- Exhibit 9: Status of Selected Medical Imaging Agents in Development (Company, Product, Status)
- Exhibit 10: World Market for Medical Contrast Media and Radiopharmaceuticals 2005-2010
- Exhibit 11: World Market Share for Medical Contrast Media and Radiopharmaceuticals by Modality (CT, MRI, PET, SPECT, Ultrasound, X-Ray), 2006
- Exhibit 12: World Market Share for Medical Contrast Media and Radiopharmaceuticals by Modality (CT, MRI, PET, SPECT, Ultrasound, X-Ray), 2010
- Exhibit 13: World Market for X-Ray Contrast Media by Geographic Segment (U.S., Europe, Japan, ROW) 2005-2010
- Exhibit 14: World Market for Medical X-Ray Contrast Media by Geographic Segment
- Exhibit 15: World Market for CT Contrast Media by Geographic Segment (U.S., Europe, Japan, ROW) 2005-2010
- Exhibit 16: World Market for Medical CT Contrast Media by Geographic Segment
- Exhibit 17: World Market for Ultrasound Contrast Media by Geographic Segment (U.S., Europe, Japan, ROW) 2005-2010
- Exhibit 18: World Market for Medical Ultrasound Contrast Media by Geographic Segment
- Exhibit 19: World Market for MRI Contrast Media by Geographic Segment (U.S., Europe, Japan, ROW) 2005-2010
- Exhibit 20: World Market for Medical MRI Contrast Media by Geographic Segment
- Exhibit 21: World Market for PET Radiopharmaceuticals by Geographic Segment (U.S., Europe, Japan, ROW) 2005-2010
- Exhibit 22: World Market for Medical PET Radiopharmaceuticals by Geographic Segment
- Exhibit 23: World Market for SPECT Radiopharmaceuticals by Geographic Segment (U.S., Europe, Japan, ROW) 2005-2010
- Exhibit 24: World Market for Medical SPECT Radiopharmaceuticals by Geographic Segment
- Exhibit 25: Key Players’ Shares of the Worldwide Medical Contrast Media Market, 2005
